Evaxion Biotech A/S
EVAX
$1.65
$0.063.77%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 67.12% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 67.12% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 67.12% | -- | -- | -- | -- |
| SG&A Expenses | -11.59% | -27.65% | -12.77% | 45.51% | 45.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.56% | -16.59% | -32.00% | -5.28% | -5.28% |
| Operating Income | 7.79% | 19.31% | 33.12% | 5.28% | 5.28% |
| Income Before Tax | 16.94% | -8.28% | 33.29% | 0.73% | 0.73% |
| Income Tax Expenses | -55.37% | 11.56% | -2.31% | -10.86% | -10.86% |
| Earnings from Continuing Operations | 19.77% | -9.06% | 34.18% | 1.08% | 1.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.77% | -9.06% | 34.18% | 1.08% | 1.08% |
| EBIT | 7.79% | 19.31% | 33.12% | 5.28% | 5.28% |
| EBITDA | 7.92% | 18.93% | 33.63% | 7.94% | 7.94% |
| EPS Basic | 56.12% | 42.86% | 45.97% | 12.50% | 12.50% |
| Normalized Basic EPS | 54.58% | 43.27% | 45.23% | 12.19% | 12.19% |
| EPS Diluted | 56.12% | 42.86% | 45.97% | 12.50% | 12.50% |
| Normalized Diluted EPS | 54.58% | 43.27% | 45.23% | 12.19% | 12.19% |
| Average Basic Shares Outstanding | 82.87% | 90.87% | 21.82% | 13.05% | 13.07% |
| Average Diluted Shares Outstanding | 82.91% | 90.74% | 21.88% | 13.05% | 13.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |